Coming Soon: Common Drug license management for all states via One single software platform

New Delhi: In order to achieve hassle-free drug licenses management for all the states in the country, CDSCO committee has decided to bring a have a common software platform and make it operational by 1st July,2019

The Drugs Consultative Committee (DCC,) functional under the Central Drugs Standard Control Organization (CDSCO) made a decision in this regard in its recent meeting.

The decision comes following the information furnished to DCC about the progress of development of the Common Software platform by the Centre for Development for Advanced Computing (CDAC), the main research and development group for the Department of Information Technology (DIT) and the Ministry of Communications and Information Technology (MCIT) in India.

CDAC made a detailed presented on online filing and processing of an application for the grant of drug manufacturing licence.

Also Read: Notice to health, commerce ministry over drug licence

Responding to the presentation, DCC stated that there should be a timeline for rolling out the programme. The committee further added the need to impart training to the state regulatory officials on the proposed software system.

After detailed deliberation, it was decided that the development of the common software platform should be completed and the programme should be rolled out on 01.07.2019.

The move is likely to ease the process of drug license management in all states of the second most populous country, thereby, establishing a much more comprehensive and transparent drug data.

Regarding training programme, it was decided that 3-5 officials of various levels from each State Drugs Control office should be nominated for training by the CDAC on 10.06.2019. Accordingly, a communication was forwarded by CDSCO to all State Drugs Controllers to depute the officials for the program.

The proposal was taken up during the 56th meeting of the DCC committee held earlier this month and various agenda of national importance for continuous strengthening of drug regulatory system in the country was closely examined.

Also Read: US industry body says India agreed to not issue COMPULSORY drug licences